SlideShare a Scribd company logo
Sepsis- overview and
management 2016
DR SUBHANKAR CHATTERJEE
Mortality
Sepsis:
30% - 50%
Septic Shock:
50% - 60%
Why we are spending time on sepsis?
Why we are spending time on sepsis?
0
50000
100000
150000
200000
250000
AIDS Breast
Cancer
AMI SEPSIS
Mortality
0
50
100
150
200
250
300
AIDS Breast
Cancer
1st MI sepsis
Incidence
Cases/100,000
Deaths/Year
The third International Consensus 2016
Definition for Sepsis ( Sepsis 3)
SEPSIS IS A
 LIFE THREATENING
 ORGAN DYSFUNCTION
 CAUSED BY A DYSREGULATED HOST
RESPONSE
 TO INFECTION
Epidemiology
Martin, G. S., Mannino, D. M., Eaton, S., & Moss, M. (2003). The
epidemiology of sepsis in the United States from 1979 through 2000.
New England Journal of Medicine, 348(16), 1546–1554.
Harrison, D. A., Welch, C. A., & Eddleston, J. M. (2006). The
epidemiology of severe sepsis in England, Wales and
Northern Ireland, 1996 to 2004: secondary analysis of a high
quality clinical database, the ICNARC Case Mix Programme
Database. Critical Care, 10(2), R42.
Brun-Buisson, C., Meshaka, P., Pinton, P., Vallet, B., EPISEPSIS
Study Group. (2004). EPISEPSIS: a reappraisal of the epidemiology
and outcome of severe sepsis in French intensive care units.
Intensive Care Medicine, 30(4), 580–588.
[1993 - 2001]...a 17%
reduction in mortality.
[1993-2001]...a
75% increase in... severe
sepsis...
Incidence
of Sepsis
Mortality
of Sepsis
Why the burden of sepsis increasing?
 Increased geriatric population
 Increasing number of immunocompromised host
 Increasing drug resistant organism
 Increasing metabolic disorder
 either
Bacteraemia (or viraemia/fungaemia/protozoan)
is the presence of bacteria within the bloodstream
Septic focus (abscess / cavity / tissue mass)
Infection
Sepsis is not merely an infection
 THE CULPRIT HERE IS OVER REACTION OF OUR
DEFENCE MECHANISM – NOT THE INVADER ALONE.
Dysregulated host response leads to..
Immune system Vs. mortality
How to suspect sepsis?
Suspect sepsis…
Altered mental status
Edema or increased fluid balance
Hyperglycemia (absent diabetes)
Hypoglyemia
Increased CRP or procalcitonin
Hypotension
Increased SvO2
CI > 3.5 L/min/m2
Arterial hypoxemia (PaO2/FiO2 < 300)
Acute oliguria (> 2 hours)
Increased serum Cr (> 0.5 mg/dL)
Coagulopathy (INR > 1.5)
Ileus (absent bowel sounds)
Thrombocytopenia (< 100,000/uL)
Hyperbilirubinemia (> 40 mg/dL or 70 mmol/L)
Hyperlactatemia (> 1 mmol/L)
Decreased capillary refill or mottling
Levy MM, et al. Crit Care Med. 2003.
How to recognize organ dysfunction?
Change in international guideline
Sepsis 2
 Sepsis = SIRS + Infection
 Infection sepsis severe
sepsis septic shock MODS
Sepsis 3
 Sepsis= infection + >2 SOFA score
from baseline
 NO Severe sepsis
SIRS to SOFA
Organ failure in sepsis
Vincent, J.-L., Sakr, Y., Sprung, C. L., Ranieri, V. M., Reinhart, K., Gerlach, H., Moreno, R., et al. (2006). Sepsis in European intensive care units: results of the SOAP study. Critical Care Medicine, 34(2), 344–353.
P/F
Platelets
Bili
BP
GCS
Cr/UOP
SOFA SCORE VARIABLES
Sequential Organ Failure Assessment (SOFA)
► Previously known as Sepsis-related Organ Failure Assessment because it was
initially developed in 1994 to describe the degree of organ dysfunction associated with
sepsis in a mixed, medical-surgical ICU patients.
► Nowadays, it has since been validated to describe the degree of organ dysfunction in
various ICU patient groups with organ dysfunctions not due to sepsis.
► The SOFA score involves six organ systems (respiratory, cardiovascular, renal, hepatic,
central nervous, coagulation), and the function of each is scored from 0 (normal
function) to 4 (most abnormal), giving a possible score of 0 to 24.
Sequential Organ Failure Assessment (SOFA)
► Mortality rate increases as number of organs with dysfunction increases.
► Unlike other scores, the worst value on each day is recorded.
► A key difference is in the cardiovascular component; instead of the composite
variable, the SOFA score uses a treatment-related variable (dose of vasopressor
agents).
Sequential Organ Failure Assessment (SOFA)
► Maximal (highest total) SOFA score: is the sum of highest scores per individual
during the entire ICU stay. A score of >15 predicted mortality of 90%.
► Mean SOFA score (ΔSOFA): is the average of all total SOFA scores in the entire ICU
stay. ΔSOFA for 1st 10 days is significantly higher in non-survivors.
► Delta SOFA score: maximum SOFA – admission SOFA
Crit Care Med 1998;26:1793-1800
Sequential Organ Failure Assessment
qSOFA for Non ICU patients with
Infection –
early recognition of severity
SEPTIC SHOCK
 Septic shock is a subset of sepsis in which
profound circulatory, cellular and
metabolic abnormalities are associated
with a greater risk of mortality than sepsis
alone
CLINICAL CRITERIA FOR SEPTIC
SHOCK 2016
 DESPITE ADEQUATE FLUID RESUSCITATION
 VASOPRESSOR NEEDED TO MAINTAIN MAP >_65mm Of
Hg AND
 LACTATE >2 MMOL/LIT
Basal lactate production
Muscle Brain RBC WBC Platelets
Renal
medulla
Gut
mucosa
Skin
0.13 mmol/
kg/hr
0.14 mmol/
kg/hr
0.18 mmol/
kg/hr
0.11 mmol/kg/hr
0.11 mmol/
kg/hr
Total = 1290 mmol / 24 hours for 70 kg
Hyperlactataemia (> 2mmol/L)
How is lactate produced?
If pyruvate production > oxidation in CAC then lactate formation increases
PDH
 Hypoxia blocks oxidative phosphorylation
 prevents NADH re-oxidation to NAD
 increases the NADH/NAD ratio
 increases the lactate/pyruvate ratio
 Normal ratio around 10:1
Cardiogenic shock
L/P ratio 40:1
Consistent with hypoxia
Resuscitated septic shock
L/P ratio 14:1
Not consistent with hypoxia
When lactate hypoperfusion
Cardiogenic shock
Hemorrhagic shock
Septic shock if
Catecholamine resistant + depressed Cardiac Index
Unresuscitated (see Rivers)
Prognostic value
 Source doesn’t matter
 High lactate still a marker of severe
physiological stress
and risk of death
 High lactate often not hypoxia
related but represents metabolic
changes of severe stress
Management of SEPSIS
 FLUIDS
 ANTIBIOTICS
 SOURCE IDENTIFICATION AND CONTROL
 VASOACTIVE DRUGS TO MAINTAIN MAP
 EARLY ORGAN SUPPORT
 LUNG PROTECTIVE VENTILATION
 AND MANY MORE…
 BUT THE MOST IMPORTANT IS A SYSTEMATIC APPROACH
System-based Approaches to sepsis
Rivers, E., Nguyen, B., Havstad, S., Ressler, J., Muzzin, A., Knoblich, B., Peterson, E., et al. (2001). Early goal-directed therapy in the treatment of severe sepsis and septic shock. New England Journal of Medicine, 345(19), 1368–1377.
System-based Approaches to sepsis
Early-Goal Directed Therapy
INCLUSION = SEPSIS AND [BP < 90 after fluid OR Lactate > 4]
CVP 8-12 Fluids CVP 8-12
MAP > 65 Vasopressors MAP > 65
Transfusions
Dobutamine
ScvO2 > 70%
49% mortality 33% mortality
Rivers, E., Nguyen, B., Havstad, S., Ressler, J., Muzzin, A., Knoblich, B., Peterson, E., et al. (2001). Early goal-directed therapy in the treatment of severe sepsis and septic shock. New England Journal of Medicine, 345(19), 1368–1377.
Control Intervention EGDT
System-based Approaches to sepsis
Rivers, E., Nguyen, B., Havstad, S., Ressler, J., Muzzin, A., Knoblich, B., Peterson, E., et al. (2001). Early goal-directed therapy in the treatment of severe sepsis and septic shock. New England Journal of Medicine, 345(19), 1368–1377.
Used to promote:
1. CVP > 8 as an initial target
2. Use of Svo2 monitoring and use of blood/dobutamine
A Multidisciplinary Community Hospital Program for Early and Rapid
Resuscitation of Shock in Non-trauma Patients
Sebat, F., Johnson, D., Musthafa, A. A., Watnik, M., Moore, S., Henry, K., & Saari, M. (2005). A multidisciplinary community hospital program for early and rapid resuscitation of shock in
nontrauma patients. Chest, 127(5), 1729–1743.
A Multidisciplinary Community Hospital Program for Early and Rapid
Resuscitation of Shock in Non-trauma Patients
Sebat, F., Johnson, D., Musthafa, A. A., Watnik, M., Moore, S., Henry, K., & Saari, M. (2005). A multidisciplinary community hospital program for early and rapid resuscitation of shock in
nontrauma patients. Chest, 127(5), 1729–1743.
Early Goal-Directed Therapy in the Treatment of Severe
Sepsis and Septic Shock
Control EGDT
Relative Risk
(95% Confidence
Interval)
P
In-Hospital 46.5 30.5
0.58
(0.38-0.87)
0.009
28-day Mortality 49.2 33.3
0.58
(0.39 – 0.87)
0.01
60-day Mortality 56.9 44.3
0.67
(0.46-0.96)
0.03
Rivers E. N Engl J Med. 2001;345: 1368-1377.
Slide 39
Copyright 2014 SCCM/ESICM
Surviving Sepsis Campaign
Suggests bundled initiative for hospitals to reduce sepsis related
mortality.
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Resuscitation Bundle Management Bundle
Compliant
Non-Compliant
TO BE COMPLETED WITHIN 3
HOURS OF TIME OF
PRESENTATION*:1. Measure lactate level
2. Obtain blood cultures prior to administration of antibiotics
3. Administer broad spectrum antibiotics
4. Administer 30ml/kg crystalloid for hypotension or lactate ≥4mmol/L
* “Time of presentation” is defined as the time of triage in the emergency
department or, if presenting from another care venue, from the earliest
chart annotation consistent with all elements of severe sepsis or septic
shock ascertained through chart review.
TO BE COMPLETED WITHIN 6
HOURS OF TIME OF
PRESENTATION:5. Apply vasopressors (for hypotension that does not
respond to initial fluid resuscitation) to maintain a mean
arterial pressure (MAP) ≥65mmHg
6. In the event of persistent hypotension after initial fluid
administration (MAP < 65 mm Hg) or if initial lactate was
≥4 mmol/L, re-assess volume status and tissue perfusion
and document findings according to Table 1
7. Re-measure lactate if initial lactate elevated
DOCUMENT REASSESSMENT OF
VOLUME STATUS AND TISSUE
PERFUSION WITH
 EITHER • Repeat focused exam (after initial fluid resuscitation) by
licensed independent practitioner including vital signs, cardiopulmonary,
capillary refill, pulse, and skin findings.
 OR TWO OF THE FOLLOWING:
 • Measure CVP
 • Measure ScvO2
 • Bedside cardiovascular ultrasound
 • Dynamic assessment of fluid responsiveness with passive leg raise or
fluid challenge
 Of note, Central Line no harm no gain. Needed for vasoactive drug
therapy.
 Bedside sonologic assessment of Volume status is prioritized.
fluid in septic shock, How much ?
IVF recommendation
 Initial fluid challenge ≥ 1000 mL of crystalloids or minimum
of 30 mL/kg of crystalloids in the 1st 4-6 hours
 (Strong recommendation; Grade 1C).
 Crystalloids is the initial fluid for resuscitation
 (Strong recommendation; Grade 1A).
 Adding albumin to the initial fluid resuscitation
 (Weak recommendation; Grade 2B).
 Against hydroxyethyl starches (hetastarches) with MW >200
dalton
 (Strong recommendation; Grade 1B).
Timing of Antibiotic Administration
Septic Shock: Timing of Antibiotics
Kumar Crit Care Med 2006
0.0
.20
.40
.60
.80
1.00
% Survival
% Total receiving antibiotics
Percent
Time, hrs
14 ICUs; n = 2,731
Only 50% of patients in Septic Shock
received antibiotics w/in 6 hrs.
G. Fluid Therapy of Severe Sepsis
H. Vasopressors
I. Inotropic Therapy
J. Corticosteroids
2. Hemodynamic Support and Adjunctive Therapy
Adrenergic Agents
Isoproterenol
Dobutamine
Dopamine
Epinephrine
Norepinephrine
Phenylephrine
Beta
Alpha
Which Inotropes to use?
 Norepinephrine as the first choice
 ( Grade 1B)
 Adding or substituting epinephrine when an additional drug is
needed
 (Strong recommendation; Grade 1B).
 Vasopressin 0.03 units/min may be added
 (Weak recommendation; Grade 2A)
 Dopamine only in highly selected patients at very low risk of
arrhythmias or low heart rate
 (Weak recommendation; Grade 2C).
 Dobutamine infusion be started or added with low cardiac output)
or ongoing signs of hypoperfusion, even after adequate
intravascular volume
 (Strong recommendation; Grade 1C)
Inotropic Therapy
• We recommend that a trial of dobutamine infusion up to 20 μg/kg/min be administered or
added to vasopressor (if in use) in the presence of:
• myocardial dysfunction as suggested by elevated cardiac filling pressures and low
cardiac output, or
• ongoing signs of hypoperfusion, despite achieving adequate intravascular volume
and adequate mean arterial pressure. (Grade 1C)
• We recommend against the use of a strategy to increase cardiac index to predetermined
supranormal levels. (Grade 1B)
Slide 53
Copyright 2014 SCCM/ESICM
Diagnosis of Infection
 Appropriate cultures before antimicrobial therapy as soon as possible (<45
minutes) (Grade 1C).
 At least two sets of blood cultures (both aerobic and anaerobic bottles)
before antimicrobial therapy, with at least one drawn percutaneously and one
drawn through each vascular access device, unless the device was recently
(<48 hours) inserted. Blood cultures can be drawn at the same time if from a
different anatomic site (Grade 1C).
Slide 54
Copyright 2014 SCCM/ESICM
Diagnosis
 Cultures of other sites (preferably quantitative where
appropriate), such as urine, cerebrospinal fluid, wounds,
respiratory secretions, or other body fluids that may be the
source of infection, should also be obtained before antimicrobial
therapy if doing so does not cause significant delay in antibiotic
administration (Grade 1C).
 We suggest the use of the 1,3 β-D-glucan assay (Grade 2B),
mannan and anti-mannan antibody assays (Grade 2C) when
invasive candidiasis is in the differential diagnosis of infection.
Slide 55
Copyright 2014 SCCM/ESICM
Diagnosis
 Imaging studies be performed promptly in attempts to
confirm a potential source of obscure infection. and
aggressive monitoring if the decision is made to transport
for a CT-guided needle aspiration) .
 Bedside studies, such as ultrasound, may avoid patient
transport (Ungraded).
Slide 56
Copyright 2014 SCCM/ESICM
Antimicrobial Therapy
 The administration of effective intravenous antimicrobials as soon
as possible , but never beyond the first hour of recognition of
SEPSIS
 Initial empiric anti-infective therapy include one or more drugs that
have activity against all likely pathogens (bacterial and/or fungal or
viral) and that penetrate in adequate concentrations into the tissues
presumed to be the source of sepsis (Grade 1B).
 The antimicrobial regimen should be reassessed daily for potential
de-escalation to prevent the development of resistance, to reduce
toxicity, and to reduce costs (Grade 1B).
Slide 57
Copyright 2014 SCCM/ESICM
Antibiotics
• Abx within 1 hr hypotension: 79.9% survival
• Survival decreased 7.6% with each hour of delay
• Mortality increased by 2nd hour post hypotension
• Time to initiation of Antibiotics was the single strongest predictor of
outcome
Antimicrobial Therapy …
 use of low procalcitonin levels or similar biomarkers to assist the
clinician in the discontinuation of empiric antibiotics in patients who
appeared septic, but have no subsequent evidence of infection
 Empiric therapy should attempt to provide antimicrobial activity against
the most likely pathogens based upon each patient’s presenting illness
and local patterns of infection.
 We suggest combination empiric therapy for neutropenic patients with
severe sepsis (Grade 2B) and for patients with difficult-to-treat,
multidrug-resistant bacterial pathogens such as Acinetobacter and
Pseudomonas spp.
Antimicrobial Therapy …
 Duration of therapy typically be 7 to 10 days if clinically indicated;
 longer courses may be appropriate in patients
 who have a slow clinical response,
 Undrainable foci of infection,
 Bacteremia with Staphylococcus aureus,
 some fungal and viral Infections, or
 Immunologic deficiencies, including neutropenia
Source Control
 When source control in a severely septic patient is required,
the effective intervention associated with the least
physiologic insult should be used (eg, percutaneous rather
than surgical drainage of an abscess) (Ungraded).
 If intravascular access devices are a possible source of
severe sepsis or septic shock, they should be removed
promptly after other vascular access has been established
(Ungraded).
Corticosteroids
 Only when Blood Pessure is not maintained with adquate flid
resuscitation and vasoacive
 Intravenous hydrocortisone alone at a dose of 200 mg per
day. Continuous Infusion preferred over bolus doses.
 Taper steroid when vasopressors are no longer required
Slide 62
Copyright 2014 SCCM/ESICM
Blood product Administration
 Transfuse PRBC only when Hb%v<7.0 g/dL to target a hemoglobin
concentration of 7.0 to 9.0 g/dL in adults (Grade 1B).
 Exceptions are myocardial ischemia, severe hypoxemia, acute
hemorrhage, or ischemic coronary artery disease.
 NO Erythropoetin in sepsis
 No FFP to correct lab abnormality in absence of Bleeding or planned
invasive procedure.
 Platelet transfusion –
 <10,000 in absence of bleeding
 <20000 if bleeding risk high
 <50,000 if planned procedure, active bleeding or surgery
Glucose Control
• We recommend protocolized approach to blood glucose
management, commencing insulin dosing when two
consecutive blood glucose levels are >180 mg/dL.
• This protocolized approach should target upper blood
glucose <180 mg/dL rather than <110 mg/dL (Grade 1A).
• Treatment should avoid hyperglycemia (>180 mg/dL),
hypoglycemia, and wide swings in glucose levels
Slide 64
Copyright 2014 SCCM/ESICM
Glucose control…
 Glucometer measured capillary blood be interpreted with
caution, as such measurements may not accurately
estimate arterial blood or plasma glucose values
 Capillary point-of-care testing found to be inaccurate with
frequent false glucose elevations over range of glucose
levels, but especially in hypoglycemic and hyperglycemic
glucose ranges and in hypotensive patients or patients
receiving catecholamines..
Bicarbonate Therapy
• No to sodium bicarbonate therapy for the purpose of
improving hemodynamics or reducing vasopressor
requirements in patients with hypoperfusion-induced lactic
acidemia with pH ≥7.15 (Grade 2B), in absence of Renal
acidosis.
Slide 66
Copyright 2014 SCCM/ESICM
Nutrition
• We suggest administering oral or enteral feedings, as
tolerated, rather than complete fasting or provision of only
intravenous glucose within the first 48 hours after a
diagnosis of severe sepsis/septic shock (Grade 2C).
• We suggest avoiding mandatory full caloric feeding in the
first week, but rather suggest low-dose feeding (e.g., up to
500 kcal per day), advancing only as tolerated
Slide 67
Copyright 2014 SCCM/ESICM
Marik and Zaloga. Crit Care Med. 2001;29:2264–2270
Heyland et al. JPEN J Parenter Enteral Nutr. 2003;27:355-373
Doig et al. Intensive Care Med. 2009;35:2018–2027
• Enteral nurtrition combined with IV Glucose supplementation
is preferred than Total parenteral Nutrition
• No evidence for the use of Arginine, Glutamine and Omega 3
fatty acid therapy during acute illness with sepsis
Nutrition…
Renal Replacement Therapy
• Continuous renal replacement therapies and intermittent
hemodialysis are equivalent in patients with sepsis and
acute renal failure because they achieve similar short-term
survival rates (Grade 2B).
• We suggest the use of continuous therapies to facilitate
management of fluid balance in hemodynamically unstable
septic patients (Grade 2D).
Slide 69
Copyright 2014 SCCM/ESICM
Prophylaxis for VTE
 We recommend that patients with severe sepsis receive daily pharmacoprophylaxis
against VTE (Grade 1B).
 We recommend that septic patients who have a contraindication to heparin not
receive pharmacoprophylaxis (Grade 1B).
 Rather, we suggest they receive mechanical prophylactic treatment, such as
graduated compression stockings or intermittent compression devices, unless
contraindicated (Grade 2C).
 When the risk decreases, we suggest starting pharmacoprophylaxis (Grade 2C).
Slide 70
Copyright 2014 SCCM/ESICM
Stress Ulcer Prophylaxis
• We recommend that stress ulcer prophylaxis using H2
blocker or proton pump inhibitor be given to patients with
sepsis/septic shock who have bleeding risk factors (Grade
1B).
• We suggest that patients without risk factors should not
receive prophylaxis (Grade 2B).
Slide 71
Copyright 2014 SCCM/ESICM
Setting Goals of Care
 We recommend that goals of care and prognosis be
discussed with patients and families (Grade 1B).
 Goals of care be incorporated into treatment and end-of-life
care planning, utilizing palliative care principles where
appropriate
 Goals of care be addressed as early as feasible, but no later
than within 72 hours of ICU admission
Slide 72
Copyright 2014 SCCM/ESICM
Take Home message
Take home message…
 Identify sepsis early
 More and faster fluid
 Send cultures early
 Antibiotic Fast <1 hr, consider early antifungals, use
biomarkers to deescalate or stop
 Earlier Inotropes, Use norepineprine
 Chase Lactic acid clearance
 Sonologic volume assessment is better than CVP
 Wet first, dry later
 Higher PEEP
THE END

More Related Content

What's hot

Inotropes & vasoactive agents
Inotropes & vasoactive agentsInotropes & vasoactive agents
Inotropes & vasoactive agents
Manoj Prabhakar
 
Sepsis and septic shock
Sepsis and septic shockSepsis and septic shock
Sepsis and septic shock
mahadev deuja
 
Sepsis presentation by shami
Sepsis presentation by shami Sepsis presentation by shami
Sepsis presentation by shami
Dr Shami Bhagat
 
Sepsis update 2021
Sepsis update 2021Sepsis update 2021
Sepsis update 2021
KTD Priyadarshani
 
Stewart approach in acid base balance
Stewart approach in acid base balanceStewart approach in acid base balance
Stewart approach in acid base balance
Dr Iyan Darmawan
 
Sepsis and septic shock
Sepsis  and septic shockSepsis  and septic shock
Sepsis and septic shock
MEEQAT HOSPITAL
 
Sepsis 3
Sepsis 3Sepsis 3
Sepsis 3
Shikha Panwar
 
Systemic Inflammatory Response Syndrome SIRS and Septicemia
Systemic Inflammatory Response Syndrome SIRS and SepticemiaSystemic Inflammatory Response Syndrome SIRS and Septicemia
Systemic Inflammatory Response Syndrome SIRS and Septicemia
Chetan Ganteppanavar
 
Septic shock; latest update
Septic shock; latest updateSeptic shock; latest update
Septic shock; latest update
Ramadan Arafa
 
Hypernatremia - Stepwise Practical Approach - Dr. Gawad
Hypernatremia - Stepwise Practical Approach - Dr. GawadHypernatremia - Stepwise Practical Approach - Dr. Gawad
Hypernatremia - Stepwise Practical Approach - Dr. Gawad
NephroTube - Dr.Gawad
 
ACUTE MANAGEMENT OF Hyperkalemia
ACUTE MANAGEMENT OF Hyperkalemia ACUTE MANAGEMENT OF Hyperkalemia
ACUTE MANAGEMENT OF Hyperkalemia
Ankit Gajjar
 
Sepsis hemodynamic update part two
Sepsis hemodynamic update      part twoSepsis hemodynamic update      part two
Sepsis hemodynamic update part two
MEEQAT HOSPITAL
 
Sepsis
SepsisSepsis
Rhabdomyolysis
RhabdomyolysisRhabdomyolysis
Rhabdomyolysis
fathi neana
 
Hepatorenal syndrome
Hepatorenal syndromeHepatorenal syndrome
Hepatorenal syndromeheyraghul
 
Surviving Sepsis Guidelines Updated
Surviving Sepsis Guidelines UpdatedSurviving Sepsis Guidelines Updated
Surviving Sepsis Guidelines Updated
Sun Yai-Cheng
 
Disorders of Sodium (Hyponatremia& Hypernatremia) : Approach & Management
Disorders of Sodium (Hyponatremia& Hypernatremia) : Approach & ManagementDisorders of Sodium (Hyponatremia& Hypernatremia) : Approach & Management
Disorders of Sodium (Hyponatremia& Hypernatremia) : Approach & Management
Abdullah Ansari
 
Sepsis for nurses
Sepsis for nursesSepsis for nurses
Sepsis for nurses
Dr fakhir Raza
 

What's hot (20)

Inotropes & vasoactive agents
Inotropes & vasoactive agentsInotropes & vasoactive agents
Inotropes & vasoactive agents
 
Sepsis and septic shock
Sepsis and septic shockSepsis and septic shock
Sepsis and septic shock
 
Sepsis presentation by shami
Sepsis presentation by shami Sepsis presentation by shami
Sepsis presentation by shami
 
Sepsis update 2021
Sepsis update 2021Sepsis update 2021
Sepsis update 2021
 
CME: Management of Severe Sepsis & Septic Shock
CME: Management of Severe Sepsis & Septic ShockCME: Management of Severe Sepsis & Septic Shock
CME: Management of Severe Sepsis & Septic Shock
 
Stewart approach in acid base balance
Stewart approach in acid base balanceStewart approach in acid base balance
Stewart approach in acid base balance
 
Sepsis and septic shock
Sepsis  and septic shockSepsis  and septic shock
Sepsis and septic shock
 
Sepsis 3
Sepsis 3Sepsis 3
Sepsis 3
 
Systemic Inflammatory Response Syndrome SIRS and Septicemia
Systemic Inflammatory Response Syndrome SIRS and SepticemiaSystemic Inflammatory Response Syndrome SIRS and Septicemia
Systemic Inflammatory Response Syndrome SIRS and Septicemia
 
Septic shock; latest update
Septic shock; latest updateSeptic shock; latest update
Septic shock; latest update
 
Hypernatremia - Stepwise Practical Approach - Dr. Gawad
Hypernatremia - Stepwise Practical Approach - Dr. GawadHypernatremia - Stepwise Practical Approach - Dr. Gawad
Hypernatremia - Stepwise Practical Approach - Dr. Gawad
 
ACUTE MANAGEMENT OF Hyperkalemia
ACUTE MANAGEMENT OF Hyperkalemia ACUTE MANAGEMENT OF Hyperkalemia
ACUTE MANAGEMENT OF Hyperkalemia
 
Sepsis hemodynamic update part two
Sepsis hemodynamic update      part twoSepsis hemodynamic update      part two
Sepsis hemodynamic update part two
 
Management of Sepsis
Management of SepsisManagement of Sepsis
Management of Sepsis
 
Sepsis
SepsisSepsis
Sepsis
 
Rhabdomyolysis
RhabdomyolysisRhabdomyolysis
Rhabdomyolysis
 
Hepatorenal syndrome
Hepatorenal syndromeHepatorenal syndrome
Hepatorenal syndrome
 
Surviving Sepsis Guidelines Updated
Surviving Sepsis Guidelines UpdatedSurviving Sepsis Guidelines Updated
Surviving Sepsis Guidelines Updated
 
Disorders of Sodium (Hyponatremia& Hypernatremia) : Approach & Management
Disorders of Sodium (Hyponatremia& Hypernatremia) : Approach & ManagementDisorders of Sodium (Hyponatremia& Hypernatremia) : Approach & Management
Disorders of Sodium (Hyponatremia& Hypernatremia) : Approach & Management
 
Sepsis for nurses
Sepsis for nursesSepsis for nurses
Sepsis for nurses
 

Similar to Sepsis 2016

Sepsis seminar final
Sepsis seminar   finalSepsis seminar   final
Sepsis seminar final
pulmonary medicine
 
Sepsis rev
Sepsis revSepsis rev
Sepsis revmurfam
 
Sepsis
SepsisSepsis
Sepsismurfam
 
Sepsis 9-2015
Sepsis  9-2015Sepsis  9-2015
mnssmnvs.pptx
mnssmnvs.pptxmnssmnvs.pptx
mnssmnvs.pptx
MakmurSejati2
 
Immunopatologi Sepsis
Immunopatologi SepsisImmunopatologi Sepsis
Immunopatologi Sepsis
DoroteaNina1
 
Multiple Organ Dysfunction Syndrome2009
Multiple Organ Dysfunction Syndrome2009Multiple Organ Dysfunction Syndrome2009
Multiple Organ Dysfunction Syndrome2009
Deep Deep
 
dr Franciscus Ginting - Sepsis PIN PAPDI Surabaya WS-051019.pdf
dr Franciscus Ginting - Sepsis PIN PAPDI  Surabaya WS-051019.pdfdr Franciscus Ginting - Sepsis PIN PAPDI  Surabaya WS-051019.pdf
dr Franciscus Ginting - Sepsis PIN PAPDI Surabaya WS-051019.pdf
corinafiqliyin
 
Pneumococcal Disease - Epidemiology & Resistance
Pneumococcal Disease - Epidemiology & ResistancePneumococcal Disease - Epidemiology & Resistance
Pneumococcal Disease - Epidemiology & Resistance
ARPUTHA SELVARAJ A
 
The State of Scleroderma Clinical Trials
The State of Scleroderma Clinical TrialsThe State of Scleroderma Clinical Trials
The State of Scleroderma Clinical Trials
Scleroderma Foundation of Greater Chicago
 
Monitoring Fluid Responsiveness in ICU
Monitoring Fluid Responsiveness in ICUMonitoring Fluid Responsiveness in ICU
Monitoring Fluid Responsiveness in ICU
Yazan Kherallah
 
Sepsis
SepsisSepsis
Sepsis
SepsisSepsis
Anaesthesia for septic patient
Anaesthesia for septic patientAnaesthesia for septic patient
Anaesthesia for septic patientArun Gupta
 
9 x fr severo en covid china
9 x fr severo en covid china9 x fr severo en covid china
9 x fr severo en covid china
Freddy Flores Malpartida
 
PSMID Urosurgical Infections
PSMID Urosurgical InfectionsPSMID Urosurgical Infections
PSMID Urosurgical Infections
Arthur Dessi Roman
 

Similar to Sepsis 2016 (20)

Sepsis seminar final
Sepsis seminar   finalSepsis seminar   final
Sepsis seminar final
 
Sepsis rev
Sepsis revSepsis rev
Sepsis rev
 
Sepsis
SepsisSepsis
Sepsis
 
Sepsis 9-2015
Sepsis  9-2015Sepsis  9-2015
Sepsis 9-2015
 
mnssmnvs.pptx
mnssmnvs.pptxmnssmnvs.pptx
mnssmnvs.pptx
 
Immunopatologi Sepsis
Immunopatologi SepsisImmunopatologi Sepsis
Immunopatologi Sepsis
 
Multiple Organ Dysfunction Syndrome2009
Multiple Organ Dysfunction Syndrome2009Multiple Organ Dysfunction Syndrome2009
Multiple Organ Dysfunction Syndrome2009
 
dr Franciscus Ginting - Sepsis PIN PAPDI Surabaya WS-051019.pdf
dr Franciscus Ginting - Sepsis PIN PAPDI  Surabaya WS-051019.pdfdr Franciscus Ginting - Sepsis PIN PAPDI  Surabaya WS-051019.pdf
dr Franciscus Ginting - Sepsis PIN PAPDI Surabaya WS-051019.pdf
 
surviving sepsis
surviving sepsissurviving sepsis
surviving sepsis
 
Pneumococcal Disease - Epidemiology & Resistance
Pneumococcal Disease - Epidemiology & ResistancePneumococcal Disease - Epidemiology & Resistance
Pneumococcal Disease - Epidemiology & Resistance
 
Sirs present
Sirs presentSirs present
Sirs present
 
The State of Scleroderma Clinical Trials
The State of Scleroderma Clinical TrialsThe State of Scleroderma Clinical Trials
The State of Scleroderma Clinical Trials
 
Monitoring Fluid Responsiveness in ICU
Monitoring Fluid Responsiveness in ICUMonitoring Fluid Responsiveness in ICU
Monitoring Fluid Responsiveness in ICU
 
Sepsis
SepsisSepsis
Sepsis
 
Sepsis
SepsisSepsis
Sepsis
 
Sepsis
SepsisSepsis
Sepsis
 
Anaesthesia for septic patient
Anaesthesia for septic patientAnaesthesia for septic patient
Anaesthesia for septic patient
 
9 x fr severo en covid china
9 x fr severo en covid china9 x fr severo en covid china
9 x fr severo en covid china
 
Sirs Mods
Sirs ModsSirs Mods
Sirs Mods
 
PSMID Urosurgical Infections
PSMID Urosurgical InfectionsPSMID Urosurgical Infections
PSMID Urosurgical Infections
 

Recently uploaded

CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfCHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
Sachin Sharma
 
Yemen National Tuberculosis Program .ppt
Yemen National Tuberculosis Program .pptYemen National Tuberculosis Program .ppt
Yemen National Tuberculosis Program .ppt
Esam43
 
Telehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptxTelehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptx
The Harvest Clinic
 
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondEmpowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Health Catalyst
 
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
Ameena Kadar
 
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
ranishasharma67
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
Rommel Luis III Israel
 
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
ranishasharma67
 
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptxBOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
AnushriSrivastav
 
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
pchutichetpong
 
The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........
TheDocs
 
ICH Guidelines for Pharmacovigilance.pdf
ICH Guidelines for Pharmacovigilance.pdfICH Guidelines for Pharmacovigilance.pdf
ICH Guidelines for Pharmacovigilance.pdf
NEHA GUPTA
 
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Dr. David Greene Arizona
 
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfCHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
Sachin Sharma
 
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.pptNursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Rommel Luis III Israel
 
CANCER CANCER CANCER CANCER CANCER CANCER
CANCER  CANCER  CANCER  CANCER  CANCER CANCERCANCER  CANCER  CANCER  CANCER  CANCER CANCER
CANCER CANCER CANCER CANCER CANCER CANCER
KRISTELLEGAMBOA2
 
Essential Metrics for Palliative Care Management
Essential Metrics for Palliative Care ManagementEssential Metrics for Palliative Care Management
Essential Metrics for Palliative Care Management
Care Coordinations
 
Navigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and BeyondNavigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and Beyond
Aboud Health Group
 
CONSTRUCTION OF TEST IN MANAGEMENT .docx
CONSTRUCTION OF TEST IN MANAGEMENT .docxCONSTRUCTION OF TEST IN MANAGEMENT .docx
CONSTRUCTION OF TEST IN MANAGEMENT .docx
PGIMS Rohtak
 
10 Ideas for Enhancing Your Meeting Experience
10 Ideas for Enhancing Your Meeting Experience10 Ideas for Enhancing Your Meeting Experience
10 Ideas for Enhancing Your Meeting Experience
ranishasharma67
 

Recently uploaded (20)

CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfCHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
 
Yemen National Tuberculosis Program .ppt
Yemen National Tuberculosis Program .pptYemen National Tuberculosis Program .ppt
Yemen National Tuberculosis Program .ppt
 
Telehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptxTelehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptx
 
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondEmpowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
 
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
 
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
 
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
 
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptxBOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
 
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
 
The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........
 
ICH Guidelines for Pharmacovigilance.pdf
ICH Guidelines for Pharmacovigilance.pdfICH Guidelines for Pharmacovigilance.pdf
ICH Guidelines for Pharmacovigilance.pdf
 
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
 
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfCHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
 
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.pptNursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
 
CANCER CANCER CANCER CANCER CANCER CANCER
CANCER  CANCER  CANCER  CANCER  CANCER CANCERCANCER  CANCER  CANCER  CANCER  CANCER CANCER
CANCER CANCER CANCER CANCER CANCER CANCER
 
Essential Metrics for Palliative Care Management
Essential Metrics for Palliative Care ManagementEssential Metrics for Palliative Care Management
Essential Metrics for Palliative Care Management
 
Navigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and BeyondNavigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and Beyond
 
CONSTRUCTION OF TEST IN MANAGEMENT .docx
CONSTRUCTION OF TEST IN MANAGEMENT .docxCONSTRUCTION OF TEST IN MANAGEMENT .docx
CONSTRUCTION OF TEST IN MANAGEMENT .docx
 
10 Ideas for Enhancing Your Meeting Experience
10 Ideas for Enhancing Your Meeting Experience10 Ideas for Enhancing Your Meeting Experience
10 Ideas for Enhancing Your Meeting Experience
 

Sepsis 2016

  • 1. Sepsis- overview and management 2016 DR SUBHANKAR CHATTERJEE
  • 2. Mortality Sepsis: 30% - 50% Septic Shock: 50% - 60% Why we are spending time on sepsis?
  • 3. Why we are spending time on sepsis? 0 50000 100000 150000 200000 250000 AIDS Breast Cancer AMI SEPSIS Mortality 0 50 100 150 200 250 300 AIDS Breast Cancer 1st MI sepsis Incidence Cases/100,000 Deaths/Year
  • 4. The third International Consensus 2016 Definition for Sepsis ( Sepsis 3) SEPSIS IS A  LIFE THREATENING  ORGAN DYSFUNCTION  CAUSED BY A DYSREGULATED HOST RESPONSE  TO INFECTION
  • 5. Epidemiology Martin, G. S., Mannino, D. M., Eaton, S., & Moss, M. (2003). The epidemiology of sepsis in the United States from 1979 through 2000. New England Journal of Medicine, 348(16), 1546–1554. Harrison, D. A., Welch, C. A., & Eddleston, J. M. (2006). The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Critical Care, 10(2), R42. Brun-Buisson, C., Meshaka, P., Pinton, P., Vallet, B., EPISEPSIS Study Group. (2004). EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Medicine, 30(4), 580–588. [1993 - 2001]...a 17% reduction in mortality. [1993-2001]...a 75% increase in... severe sepsis... Incidence of Sepsis Mortality of Sepsis
  • 6. Why the burden of sepsis increasing?  Increased geriatric population  Increasing number of immunocompromised host  Increasing drug resistant organism  Increasing metabolic disorder
  • 7.  either Bacteraemia (or viraemia/fungaemia/protozoan) is the presence of bacteria within the bloodstream Septic focus (abscess / cavity / tissue mass) Infection
  • 8. Sepsis is not merely an infection  THE CULPRIT HERE IS OVER REACTION OF OUR DEFENCE MECHANISM – NOT THE INVADER ALONE.
  • 9.
  • 11. Immune system Vs. mortality
  • 12. How to suspect sepsis?
  • 14. Altered mental status Edema or increased fluid balance Hyperglycemia (absent diabetes) Hypoglyemia Increased CRP or procalcitonin Hypotension Increased SvO2 CI > 3.5 L/min/m2 Arterial hypoxemia (PaO2/FiO2 < 300) Acute oliguria (> 2 hours) Increased serum Cr (> 0.5 mg/dL) Coagulopathy (INR > 1.5) Ileus (absent bowel sounds) Thrombocytopenia (< 100,000/uL) Hyperbilirubinemia (> 40 mg/dL or 70 mmol/L) Hyperlactatemia (> 1 mmol/L) Decreased capillary refill or mottling Levy MM, et al. Crit Care Med. 2003. How to recognize organ dysfunction?
  • 15. Change in international guideline Sepsis 2  Sepsis = SIRS + Infection  Infection sepsis severe sepsis septic shock MODS Sepsis 3  Sepsis= infection + >2 SOFA score from baseline  NO Severe sepsis
  • 17. Organ failure in sepsis Vincent, J.-L., Sakr, Y., Sprung, C. L., Ranieri, V. M., Reinhart, K., Gerlach, H., Moreno, R., et al. (2006). Sepsis in European intensive care units: results of the SOAP study. Critical Care Medicine, 34(2), 344–353. P/F Platelets Bili BP GCS Cr/UOP
  • 19. Sequential Organ Failure Assessment (SOFA) ► Previously known as Sepsis-related Organ Failure Assessment because it was initially developed in 1994 to describe the degree of organ dysfunction associated with sepsis in a mixed, medical-surgical ICU patients. ► Nowadays, it has since been validated to describe the degree of organ dysfunction in various ICU patient groups with organ dysfunctions not due to sepsis. ► The SOFA score involves six organ systems (respiratory, cardiovascular, renal, hepatic, central nervous, coagulation), and the function of each is scored from 0 (normal function) to 4 (most abnormal), giving a possible score of 0 to 24.
  • 20. Sequential Organ Failure Assessment (SOFA) ► Mortality rate increases as number of organs with dysfunction increases. ► Unlike other scores, the worst value on each day is recorded. ► A key difference is in the cardiovascular component; instead of the composite variable, the SOFA score uses a treatment-related variable (dose of vasopressor agents).
  • 21. Sequential Organ Failure Assessment (SOFA) ► Maximal (highest total) SOFA score: is the sum of highest scores per individual during the entire ICU stay. A score of >15 predicted mortality of 90%. ► Mean SOFA score (ΔSOFA): is the average of all total SOFA scores in the entire ICU stay. ΔSOFA for 1st 10 days is significantly higher in non-survivors. ► Delta SOFA score: maximum SOFA – admission SOFA Crit Care Med 1998;26:1793-1800
  • 23. qSOFA for Non ICU patients with Infection – early recognition of severity
  • 24. SEPTIC SHOCK  Septic shock is a subset of sepsis in which profound circulatory, cellular and metabolic abnormalities are associated with a greater risk of mortality than sepsis alone
  • 25. CLINICAL CRITERIA FOR SEPTIC SHOCK 2016  DESPITE ADEQUATE FLUID RESUSCITATION  VASOPRESSOR NEEDED TO MAINTAIN MAP >_65mm Of Hg AND  LACTATE >2 MMOL/LIT
  • 26. Basal lactate production Muscle Brain RBC WBC Platelets Renal medulla Gut mucosa Skin 0.13 mmol/ kg/hr 0.14 mmol/ kg/hr 0.18 mmol/ kg/hr 0.11 mmol/kg/hr 0.11 mmol/ kg/hr Total = 1290 mmol / 24 hours for 70 kg
  • 28. How is lactate produced? If pyruvate production > oxidation in CAC then lactate formation increases PDH
  • 29.  Hypoxia blocks oxidative phosphorylation  prevents NADH re-oxidation to NAD  increases the NADH/NAD ratio  increases the lactate/pyruvate ratio  Normal ratio around 10:1 Cardiogenic shock L/P ratio 40:1 Consistent with hypoxia Resuscitated septic shock L/P ratio 14:1 Not consistent with hypoxia
  • 30. When lactate hypoperfusion Cardiogenic shock Hemorrhagic shock Septic shock if Catecholamine resistant + depressed Cardiac Index Unresuscitated (see Rivers)
  • 31. Prognostic value  Source doesn’t matter  High lactate still a marker of severe physiological stress and risk of death  High lactate often not hypoxia related but represents metabolic changes of severe stress
  • 32.
  • 33. Management of SEPSIS  FLUIDS  ANTIBIOTICS  SOURCE IDENTIFICATION AND CONTROL  VASOACTIVE DRUGS TO MAINTAIN MAP  EARLY ORGAN SUPPORT  LUNG PROTECTIVE VENTILATION  AND MANY MORE…  BUT THE MOST IMPORTANT IS A SYSTEMATIC APPROACH
  • 34. System-based Approaches to sepsis Rivers, E., Nguyen, B., Havstad, S., Ressler, J., Muzzin, A., Knoblich, B., Peterson, E., et al. (2001). Early goal-directed therapy in the treatment of severe sepsis and septic shock. New England Journal of Medicine, 345(19), 1368–1377.
  • 35. System-based Approaches to sepsis Early-Goal Directed Therapy INCLUSION = SEPSIS AND [BP < 90 after fluid OR Lactate > 4] CVP 8-12 Fluids CVP 8-12 MAP > 65 Vasopressors MAP > 65 Transfusions Dobutamine ScvO2 > 70% 49% mortality 33% mortality Rivers, E., Nguyen, B., Havstad, S., Ressler, J., Muzzin, A., Knoblich, B., Peterson, E., et al. (2001). Early goal-directed therapy in the treatment of severe sepsis and septic shock. New England Journal of Medicine, 345(19), 1368–1377. Control Intervention EGDT
  • 36. System-based Approaches to sepsis Rivers, E., Nguyen, B., Havstad, S., Ressler, J., Muzzin, A., Knoblich, B., Peterson, E., et al. (2001). Early goal-directed therapy in the treatment of severe sepsis and septic shock. New England Journal of Medicine, 345(19), 1368–1377. Used to promote: 1. CVP > 8 as an initial target 2. Use of Svo2 monitoring and use of blood/dobutamine
  • 37. A Multidisciplinary Community Hospital Program for Early and Rapid Resuscitation of Shock in Non-trauma Patients Sebat, F., Johnson, D., Musthafa, A. A., Watnik, M., Moore, S., Henry, K., & Saari, M. (2005). A multidisciplinary community hospital program for early and rapid resuscitation of shock in nontrauma patients. Chest, 127(5), 1729–1743.
  • 38. A Multidisciplinary Community Hospital Program for Early and Rapid Resuscitation of Shock in Non-trauma Patients Sebat, F., Johnson, D., Musthafa, A. A., Watnik, M., Moore, S., Henry, K., & Saari, M. (2005). A multidisciplinary community hospital program for early and rapid resuscitation of shock in nontrauma patients. Chest, 127(5), 1729–1743.
  • 39. Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock Control EGDT Relative Risk (95% Confidence Interval) P In-Hospital 46.5 30.5 0.58 (0.38-0.87) 0.009 28-day Mortality 49.2 33.3 0.58 (0.39 – 0.87) 0.01 60-day Mortality 56.9 44.3 0.67 (0.46-0.96) 0.03 Rivers E. N Engl J Med. 2001;345: 1368-1377. Slide 39 Copyright 2014 SCCM/ESICM
  • 40. Surviving Sepsis Campaign Suggests bundled initiative for hospitals to reduce sepsis related mortality. 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 Resuscitation Bundle Management Bundle Compliant Non-Compliant
  • 41. TO BE COMPLETED WITHIN 3 HOURS OF TIME OF PRESENTATION*:1. Measure lactate level 2. Obtain blood cultures prior to administration of antibiotics 3. Administer broad spectrum antibiotics 4. Administer 30ml/kg crystalloid for hypotension or lactate ≥4mmol/L * “Time of presentation” is defined as the time of triage in the emergency department or, if presenting from another care venue, from the earliest chart annotation consistent with all elements of severe sepsis or septic shock ascertained through chart review.
  • 42. TO BE COMPLETED WITHIN 6 HOURS OF TIME OF PRESENTATION:5. Apply vasopressors (for hypotension that does not respond to initial fluid resuscitation) to maintain a mean arterial pressure (MAP) ≥65mmHg 6. In the event of persistent hypotension after initial fluid administration (MAP < 65 mm Hg) or if initial lactate was ≥4 mmol/L, re-assess volume status and tissue perfusion and document findings according to Table 1 7. Re-measure lactate if initial lactate elevated
  • 43. DOCUMENT REASSESSMENT OF VOLUME STATUS AND TISSUE PERFUSION WITH  EITHER • Repeat focused exam (after initial fluid resuscitation) by licensed independent practitioner including vital signs, cardiopulmonary, capillary refill, pulse, and skin findings.  OR TWO OF THE FOLLOWING:  • Measure CVP  • Measure ScvO2  • Bedside cardiovascular ultrasound  • Dynamic assessment of fluid responsiveness with passive leg raise or fluid challenge  Of note, Central Line no harm no gain. Needed for vasoactive drug therapy.  Bedside sonologic assessment of Volume status is prioritized.
  • 44.
  • 45. fluid in septic shock, How much ?
  • 46. IVF recommendation  Initial fluid challenge ≥ 1000 mL of crystalloids or minimum of 30 mL/kg of crystalloids in the 1st 4-6 hours  (Strong recommendation; Grade 1C).  Crystalloids is the initial fluid for resuscitation  (Strong recommendation; Grade 1A).  Adding albumin to the initial fluid resuscitation  (Weak recommendation; Grade 2B).  Against hydroxyethyl starches (hetastarches) with MW >200 dalton  (Strong recommendation; Grade 1B).
  • 47. Timing of Antibiotic Administration
  • 48. Septic Shock: Timing of Antibiotics Kumar Crit Care Med 2006 0.0 .20 .40 .60 .80 1.00 % Survival % Total receiving antibiotics Percent Time, hrs 14 ICUs; n = 2,731 Only 50% of patients in Septic Shock received antibiotics w/in 6 hrs.
  • 49. G. Fluid Therapy of Severe Sepsis H. Vasopressors I. Inotropic Therapy J. Corticosteroids 2. Hemodynamic Support and Adjunctive Therapy
  • 51. Which Inotropes to use?  Norepinephrine as the first choice  ( Grade 1B)  Adding or substituting epinephrine when an additional drug is needed  (Strong recommendation; Grade 1B).  Vasopressin 0.03 units/min may be added  (Weak recommendation; Grade 2A)  Dopamine only in highly selected patients at very low risk of arrhythmias or low heart rate  (Weak recommendation; Grade 2C).  Dobutamine infusion be started or added with low cardiac output) or ongoing signs of hypoperfusion, even after adequate intravascular volume  (Strong recommendation; Grade 1C)
  • 52. Inotropic Therapy • We recommend that a trial of dobutamine infusion up to 20 μg/kg/min be administered or added to vasopressor (if in use) in the presence of: • myocardial dysfunction as suggested by elevated cardiac filling pressures and low cardiac output, or • ongoing signs of hypoperfusion, despite achieving adequate intravascular volume and adequate mean arterial pressure. (Grade 1C) • We recommend against the use of a strategy to increase cardiac index to predetermined supranormal levels. (Grade 1B) Slide 53 Copyright 2014 SCCM/ESICM
  • 53. Diagnosis of Infection  Appropriate cultures before antimicrobial therapy as soon as possible (<45 minutes) (Grade 1C).  At least two sets of blood cultures (both aerobic and anaerobic bottles) before antimicrobial therapy, with at least one drawn percutaneously and one drawn through each vascular access device, unless the device was recently (<48 hours) inserted. Blood cultures can be drawn at the same time if from a different anatomic site (Grade 1C). Slide 54 Copyright 2014 SCCM/ESICM
  • 54. Diagnosis  Cultures of other sites (preferably quantitative where appropriate), such as urine, cerebrospinal fluid, wounds, respiratory secretions, or other body fluids that may be the source of infection, should also be obtained before antimicrobial therapy if doing so does not cause significant delay in antibiotic administration (Grade 1C).  We suggest the use of the 1,3 β-D-glucan assay (Grade 2B), mannan and anti-mannan antibody assays (Grade 2C) when invasive candidiasis is in the differential diagnosis of infection. Slide 55 Copyright 2014 SCCM/ESICM
  • 55. Diagnosis  Imaging studies be performed promptly in attempts to confirm a potential source of obscure infection. and aggressive monitoring if the decision is made to transport for a CT-guided needle aspiration) .  Bedside studies, such as ultrasound, may avoid patient transport (Ungraded). Slide 56 Copyright 2014 SCCM/ESICM
  • 56. Antimicrobial Therapy  The administration of effective intravenous antimicrobials as soon as possible , but never beyond the first hour of recognition of SEPSIS  Initial empiric anti-infective therapy include one or more drugs that have activity against all likely pathogens (bacterial and/or fungal or viral) and that penetrate in adequate concentrations into the tissues presumed to be the source of sepsis (Grade 1B).  The antimicrobial regimen should be reassessed daily for potential de-escalation to prevent the development of resistance, to reduce toxicity, and to reduce costs (Grade 1B). Slide 57 Copyright 2014 SCCM/ESICM
  • 57. Antibiotics • Abx within 1 hr hypotension: 79.9% survival • Survival decreased 7.6% with each hour of delay • Mortality increased by 2nd hour post hypotension • Time to initiation of Antibiotics was the single strongest predictor of outcome
  • 58. Antimicrobial Therapy …  use of low procalcitonin levels or similar biomarkers to assist the clinician in the discontinuation of empiric antibiotics in patients who appeared septic, but have no subsequent evidence of infection  Empiric therapy should attempt to provide antimicrobial activity against the most likely pathogens based upon each patient’s presenting illness and local patterns of infection.  We suggest combination empiric therapy for neutropenic patients with severe sepsis (Grade 2B) and for patients with difficult-to-treat, multidrug-resistant bacterial pathogens such as Acinetobacter and Pseudomonas spp.
  • 59. Antimicrobial Therapy …  Duration of therapy typically be 7 to 10 days if clinically indicated;  longer courses may be appropriate in patients  who have a slow clinical response,  Undrainable foci of infection,  Bacteremia with Staphylococcus aureus,  some fungal and viral Infections, or  Immunologic deficiencies, including neutropenia
  • 60. Source Control  When source control in a severely septic patient is required, the effective intervention associated with the least physiologic insult should be used (eg, percutaneous rather than surgical drainage of an abscess) (Ungraded).  If intravascular access devices are a possible source of severe sepsis or septic shock, they should be removed promptly after other vascular access has been established (Ungraded).
  • 61. Corticosteroids  Only when Blood Pessure is not maintained with adquate flid resuscitation and vasoacive  Intravenous hydrocortisone alone at a dose of 200 mg per day. Continuous Infusion preferred over bolus doses.  Taper steroid when vasopressors are no longer required Slide 62 Copyright 2014 SCCM/ESICM
  • 62. Blood product Administration  Transfuse PRBC only when Hb%v<7.0 g/dL to target a hemoglobin concentration of 7.0 to 9.0 g/dL in adults (Grade 1B).  Exceptions are myocardial ischemia, severe hypoxemia, acute hemorrhage, or ischemic coronary artery disease.  NO Erythropoetin in sepsis  No FFP to correct lab abnormality in absence of Bleeding or planned invasive procedure.  Platelet transfusion –  <10,000 in absence of bleeding  <20000 if bleeding risk high  <50,000 if planned procedure, active bleeding or surgery
  • 63. Glucose Control • We recommend protocolized approach to blood glucose management, commencing insulin dosing when two consecutive blood glucose levels are >180 mg/dL. • This protocolized approach should target upper blood glucose <180 mg/dL rather than <110 mg/dL (Grade 1A). • Treatment should avoid hyperglycemia (>180 mg/dL), hypoglycemia, and wide swings in glucose levels Slide 64 Copyright 2014 SCCM/ESICM
  • 64. Glucose control…  Glucometer measured capillary blood be interpreted with caution, as such measurements may not accurately estimate arterial blood or plasma glucose values  Capillary point-of-care testing found to be inaccurate with frequent false glucose elevations over range of glucose levels, but especially in hypoglycemic and hyperglycemic glucose ranges and in hypotensive patients or patients receiving catecholamines..
  • 65. Bicarbonate Therapy • No to sodium bicarbonate therapy for the purpose of improving hemodynamics or reducing vasopressor requirements in patients with hypoperfusion-induced lactic acidemia with pH ≥7.15 (Grade 2B), in absence of Renal acidosis. Slide 66 Copyright 2014 SCCM/ESICM
  • 66. Nutrition • We suggest administering oral or enteral feedings, as tolerated, rather than complete fasting or provision of only intravenous glucose within the first 48 hours after a diagnosis of severe sepsis/septic shock (Grade 2C). • We suggest avoiding mandatory full caloric feeding in the first week, but rather suggest low-dose feeding (e.g., up to 500 kcal per day), advancing only as tolerated Slide 67 Copyright 2014 SCCM/ESICM Marik and Zaloga. Crit Care Med. 2001;29:2264–2270 Heyland et al. JPEN J Parenter Enteral Nutr. 2003;27:355-373 Doig et al. Intensive Care Med. 2009;35:2018–2027
  • 67. • Enteral nurtrition combined with IV Glucose supplementation is preferred than Total parenteral Nutrition • No evidence for the use of Arginine, Glutamine and Omega 3 fatty acid therapy during acute illness with sepsis Nutrition…
  • 68. Renal Replacement Therapy • Continuous renal replacement therapies and intermittent hemodialysis are equivalent in patients with sepsis and acute renal failure because they achieve similar short-term survival rates (Grade 2B). • We suggest the use of continuous therapies to facilitate management of fluid balance in hemodynamically unstable septic patients (Grade 2D). Slide 69 Copyright 2014 SCCM/ESICM
  • 69. Prophylaxis for VTE  We recommend that patients with severe sepsis receive daily pharmacoprophylaxis against VTE (Grade 1B).  We recommend that septic patients who have a contraindication to heparin not receive pharmacoprophylaxis (Grade 1B).  Rather, we suggest they receive mechanical prophylactic treatment, such as graduated compression stockings or intermittent compression devices, unless contraindicated (Grade 2C).  When the risk decreases, we suggest starting pharmacoprophylaxis (Grade 2C). Slide 70 Copyright 2014 SCCM/ESICM
  • 70. Stress Ulcer Prophylaxis • We recommend that stress ulcer prophylaxis using H2 blocker or proton pump inhibitor be given to patients with sepsis/septic shock who have bleeding risk factors (Grade 1B). • We suggest that patients without risk factors should not receive prophylaxis (Grade 2B). Slide 71 Copyright 2014 SCCM/ESICM
  • 71. Setting Goals of Care  We recommend that goals of care and prognosis be discussed with patients and families (Grade 1B).  Goals of care be incorporated into treatment and end-of-life care planning, utilizing palliative care principles where appropriate  Goals of care be addressed as early as feasible, but no later than within 72 hours of ICU admission Slide 72 Copyright 2014 SCCM/ESICM
  • 73. Take home message…  Identify sepsis early  More and faster fluid  Send cultures early  Antibiotic Fast <1 hr, consider early antifungals, use biomarkers to deescalate or stop  Earlier Inotropes, Use norepineprine  Chase Lactic acid clearance  Sonologic volume assessment is better than CVP  Wet first, dry later  Higher PEEP